Brief: Zelira Therapeutics Says FY Net Loss Attributable A$12.4 Million
31/08/2022 07:36
Aug 31 (Reuters) - Zelira Therapeutics Ltd ZLD.AX :
* FY NET LOSS ATTRIBUTABLE A$12.4 MILLION
* FY REVENUE EXCLUDING INTEREST RECEIVED A$1.5 MILLION
Further company coverage: ZLD.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Zelira Therapeutics
See all newsBrief: Zelira Therapeutics Announces $33 MLN Fundraising Into Zeliras HOPE 1 SPV
Australia's Zelira Therapeutics surges on $33 million funding for drug trial
Australia's Zelira Therapeutics climbs to over 7-month high on securing patents
Brief: Zelira Therapeutics Receives USD$1.4 Million Unsecured Loan Funds From Chairman
Brief: Zelira Therapeutics Ltd Says Zld Secures Us$1.4M Unsecured Chairman Loan Facility